This is a start up company and nothing more. Those who
ignore this fact may end up regretting it. It is not Merck.
It is not Pfizer. It is Cytogenix, still a developemental stage company, with good technology, but still a high risk investment no matter how one cuts it.
holycow, this post is not aimed at you in partular. It is just a reminder to those who may be under the impression
that this is a real company with real revenues. When the revenues start to come in to pay for additional R&D, IND apps, phase trial expenses, then I believe CYGX will be have won half the battle. Right now it is a battle to just to get to that point and I am very optimistic.
